<table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="tbl2" position="float"><object-id pub-id-type="doi">10.7554/eLife.01267.012</object-id><label>Table 2.</label><caption><p>Candidate list of seizure-dependent NRSF regulated genes</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.01267.012">http://dx.doi.org/10.7554/eLife.01267.012</ext-link></p></caption><table frame="hsides" rules="groups"><tbody><tr><td colspan="5">Ion channels, accessory subunits or receptors</td></tr><tr><td>HCN1</td><td>hyperpolarization-activated cyclic nucleotide-gated channel 1 (Hcn1)</td><td><xref ref-type="table-fn" rid="tblfn1">*</xref></td><td><xref ref-type="table-fn" rid="tblfn2">&#8224;</xref></td><td><xref ref-type="table-fn" rid="tblfn3">&#8225;</xref></td></tr><tr><td>LRP11</td><td>low density lipoprotein receptor-related protein 11</td><td><xref ref-type="table-fn" rid="tblfn1">*</xref></td><td><xref ref-type="table-fn" rid="tblfn2">&#8224;</xref></td><td><xref ref-type="table-fn" rid="tblfn3">&#8225;</xref></td></tr><tr><td>KCNC2</td><td>potassium voltage gated channel, Shaw-related subfamily, member 2</td><td><xref ref-type="table-fn" rid="tblfn1">*</xref></td><td><xref ref-type="table-fn" rid="tblfn2">&#8224;</xref></td><td><xref ref-type="table-fn" rid="tblfn3">&#8225;</xref></td></tr><tr><td>KCNIP2</td><td>Kv channel-interacting protein 2 (Kcnip2), transcript variant a</td><td><xref ref-type="table-fn" rid="tblfn1">*</xref></td><td><xref ref-type="table-fn" rid="tblfn2">&#8224;</xref></td><td/></tr><tr><td>BAI2</td><td>brain-specific angiogenesis inhibitor 2 (predicted)</td><td><xref ref-type="table-fn" rid="tblfn1">*</xref></td><td><xref ref-type="table-fn" rid="tblfn2">&#8224;</xref></td><td/></tr><tr><td>SCN3B</td><td>sodium channel, voltage-gated, type III, beta (Scn3b)</td><td><xref ref-type="table-fn" rid="tblfn1">*</xref></td><td/><td/></tr><tr><td>SLC12A5</td><td>solute carrier family 12 member 5 (Slc12a5), (KCC2)</td><td><xref ref-type="table-fn" rid="tblfn1">*</xref></td><td/><td/></tr><tr><td>GRIN2A</td><td>Glutamate receptor, ionotropic, N-methyl D-aspartate 2A (Grin2a)</td><td><xref ref-type="table-fn" rid="tblfn1">*</xref></td><td/><td/></tr><tr><td>KCNC1</td><td>K voltage gated channel, Shaw-related subfamily, member 1, transcript 2 (Kcnc1)</td><td><xref ref-type="table-fn" rid="tblfn1">*</xref></td><td/><td/></tr><tr><td>GLRA2</td><td>glycine receptor, alpha 2 (Glra2)</td><td><xref ref-type="table-fn" rid="tblfn1">*</xref></td><td/><td/></tr><tr><td>NTRK3</td><td>neurotrophic tyrosine kinase, receptor, type 3 (Ntrk3)</td><td><xref ref-type="table-fn" rid="tblfn1">*</xref></td><td/><td/></tr><tr><td colspan="5">Calcium-mediated cellular cascades</td></tr><tr><td>CADPS</td><td>Ca++-dependent secretion activator (Cadps)</td><td><xref ref-type="table-fn" rid="tblfn1">*</xref></td><td><xref ref-type="table-fn" rid="tblfn2">&#8224;</xref></td><td><xref ref-type="table-fn" rid="tblfn3">&#8225;</xref></td></tr><tr><td>CALB1</td><td>calbindin 1 (Calb1)</td><td><xref ref-type="table-fn" rid="tblfn1">*</xref></td><td><xref ref-type="table-fn" rid="tblfn2">&#8224;</xref></td><td/></tr><tr><td>HPCA</td><td>hippocalcin (Hpca)</td><td><xref ref-type="table-fn" rid="tblfn1">*</xref></td><td><xref ref-type="table-fn" rid="tblfn2">&#8224;</xref></td><td/></tr><tr><td>CABP7</td><td>calcium binding protein 7 (Cabp7)</td><td><xref ref-type="table-fn" rid="tblfn1">*</xref></td><td><xref ref-type="table-fn" rid="tblfn2">&#8224;</xref></td><td/></tr><tr><td>MYO5B</td><td>myosin Vb (Myo5b)</td><td><xref ref-type="table-fn" rid="tblfn1">*</xref></td><td/><td/></tr><tr><td>CAMKV</td><td>CaM kinase-like vesicle-associated (Camkv)</td><td><xref ref-type="table-fn" rid="tblfn1">*</xref></td><td/><td/></tr><tr><td colspan="5">Phosphoenzymes</td></tr><tr><td>GNAO1</td><td>guanine nucleotide binding protein, alpha O (Gnao1)</td><td><xref ref-type="table-fn" rid="tblfn1">*</xref></td><td><xref ref-type="table-fn" rid="tblfn2">&#8224;</xref></td><td><xref ref-type="table-fn" rid="tblfn3">&#8225;</xref></td></tr><tr><td>PRKCG</td><td>protein kinase C, gamma (Prkcg)</td><td><xref ref-type="table-fn" rid="tblfn1">*</xref></td><td/><td/></tr><tr><td>PRKCB1</td><td>protein kinase C, beta 1 (Prkcb1)</td><td><xref ref-type="table-fn" rid="tblfn1">*</xref></td><td/><td/></tr><tr><td>NELL1</td><td>NEL-like 1 (chicken) (Nell1)</td><td><xref ref-type="table-fn" rid="tblfn1">*</xref></td><td/><td/></tr><tr><td colspan="5">Others</td></tr><tr><td>KLF9</td><td>Kruppel-like factor 9 (Klf9)</td><td><xref ref-type="table-fn" rid="tblfn1">*</xref></td><td><xref ref-type="table-fn" rid="tblfn2">&#8224;</xref></td><td><xref ref-type="table-fn" rid="tblfn3">&#8225;</xref></td></tr><tr><td>STMN2</td><td>stathmin-like 2 (Stmn2)</td><td><xref ref-type="table-fn" rid="tblfn1">*</xref></td><td><xref ref-type="table-fn" rid="tblfn2">&#8224;</xref></td><td/></tr><tr><td>OLFM3</td><td>olfactomedin 3 (Olfm3)</td><td><xref ref-type="table-fn" rid="tblfn1">*</xref></td><td><xref ref-type="table-fn" rid="tblfn2">&#8224;</xref></td><td/></tr><tr><td>ICA1</td><td>islet cell autoantigen 1 (Ica1)</td><td><xref ref-type="table-fn" rid="tblfn1">*</xref></td><td><xref ref-type="table-fn" rid="tblfn2">&#8224;</xref></td><td/></tr><tr><td>STMN3</td><td>stathmin-like 3 (Stmn3)</td><td><xref ref-type="table-fn" rid="tblfn1">*</xref></td><td/><td/></tr><tr><td>OLFM1</td><td>olfactomedin 1 (Olfm1)</td><td><xref ref-type="table-fn" rid="tblfn1">*</xref></td><td/><td/></tr><tr><td>NXPH1</td><td>neurexophilin 1 (Nxph1)</td><td><xref ref-type="table-fn" rid="tblfn1">*</xref></td><td/><td/></tr></tbody></table><table-wrap-foot><fn><p>Genes were designated as &#8216;NRSE-containing&#8217; based on NRSF ChIP-sequencing data from previous studies (<xref ref-type="bibr" rid="bib31">Johnson et al., 2007</xref>). For inclusion in the initial list of candidate genes for NRSF regulation, genes were considered significantly repressed if their expression was reduced by more than 20% after KA-induced seizures (p &lt; 0.05). Genes considered &#8216;rescued&#8217; were significantly repressed after seizures but not significantly repressed after ODN infusions [seizures + NRSE-ODN treatment]. This candidate gene approach was followed by measures to correct for FDR (see &#8216;Materials and methods&#8217;).</p></fn><fn id="tblfn1"><label>*</label><p>genes (28) with expression reduced by &gt; 20% after KA-induced activity, and rescued by NRSF ODN; p &lt; 0.05.</p></fn><fn id="tblfn2"><label>&#8224;</label><p>genes (14) found with ANOVA, Benjamini&#8211;Hochberg FDR &lt;0.25.</p></fn><fn id="tblfn3"><label>&#8225;</label><p>genes (6) found with one-way ANOVA, unadjusted p value &lt;0.05.</p></fn></table-wrap-foot></table-wrap>